Sofie and PerkinElmer to market preclinical hybrids, biopharmaceuticals

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

PerkinElmer announced an agreement with Sofie Biosciences this month to commercialize the latter's preclinical PET, 3D CT and X-ray systems.

In addition to these hybrid imaging systems, the Culver City, Calif., based company will be working directly with PerkinElmer to develop strategies for expanding Sofie’s biopharmaceutical development.

"Our relationship combines PerkinElmer's preclinical leadership with Sofie's PET expertise to bring new translational imaging solutions to the global research community," said Patrick Phelps, president and CEO of Sofie Biosciences, in a press release.

The partnership will be focusing on areas of research in pharmacology, oncology, immunology, cardiology and neurobiology. A new preclinical PET/CT system is in the wings.

"As a leading provider of imaging platforms for cellular, tissue and in vivo research, PerkinElmer is pleased to partner with Sofie, a leader in the field of PET imaging, to deliver these systems to the global preclinical research community," said PerkinElmer Life Sciences and Technology president Brian Kim. "In vivo preclinical imaging plays an integral role in translational research and drug discovery, facilitating a unique understanding of disease initiation, progression and therapeutic responses."

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.